Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.
The Canadian Medical Association endorses the 2015 revision of the World Medical Association Statement on Nuclear Weapons (https://www.wma.net/policies-post/wma-statement-on-nuclear-weapons/) [Please copy and paste this link into your web browser.]
The Canadian Medical Association endorses the 2015 revision of the World Medical Association Statement on Nuclear Weapons (https://www.wma.net/policies-post/wma-statement-on-nuclear-weapons/) [Please copy and paste this link into your web browser.]
The Canadian Medical Association recommends that the Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain include consideration of pharmacokinetic and pharmacodynamic factors specific to older adults.
The Canadian Medical Association recommends that the Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain include consideration of pharmacokinetic and pharmacodynamic factors specific to older adults.
The Canadian Medical Association advocates for the development of national standardized non-pharmacologic order sets for the treatment of older adults with delirium.
The Canadian Medical Association advocates for the development of national standardized non-pharmacologic order sets for the treatment of older adults with delirium.
The Canadian Medical Association calls for the addition of low-risk guidelines specific to people aged 65 or older to augment "Canada’s Low-Risk Alcohol Drinking Guidelines."
The Canadian Medical Association calls for the addition of low-risk guidelines specific to people aged 65 or older to augment "Canada’s Low-Risk Alcohol Drinking Guidelines."
The Canadian Medical Association supports inclusion of the cost of neuropsychological assessments of all patients suspected of fetal alcohol spectrum disorder as an insured-benefit.
The Canadian Medical Association supports inclusion of the cost of neuropsychological assessments of all patients suspected of fetal alcohol spectrum disorder as an insured-benefit.
